### Editorials

**Methotrexate Therapy for Psoriatic Arthritis: Reappraisal of an Old Remedy**
L.A. Saketkoo, R. Cuchacovich, L.R. Espinoza .......................... 369

**Lessons from Magnetic Resonance Imaging Studies in Rheumatoid Arthritis**
M. Quinn .................................................. 372

**Infections, Drugs, and Rheumatoid Arthritis. What Have We Learned?**
J.S. Coblyn ........................................... 375

**Diffuse Idiopathic Skeletal Hyperostosis: Time for a Change**
R. Mader .................................................. 377

### Articles

**Anemia in Early RA Is Associated with IL-6-Mediated Bone Marrow Suppression, But Has No Effect on Disease Course or Mortality**
C. Nikolaisen, Y. Figenschau, J.C. Nossent .......................... 380

**The Risk of Hospitalized Infection in Patients with RA**

**Etanercept Reduces Synovitis as Measured by MRI in Patients with Active RA After Only 6 Weeks**

**Endothelial Dysfunction and Atherosclerosis in RA: A Multiparametric Analysis Using Imaging Techniques and Laboratory Markers of Inflammation and Autoimmunity**

**Osteoclast Inhibitory Effects of Vitamin K$_2$ Alone or in Combination with Etidronate or Risedronate in Patients with RA: 2-Year Results**

**Easy and Accurate Diagnosis of RA Using Anti-CCP2 Antibody, Swollen Joint Count, and CRP/RF**
T. Yamane, A. Hashiramoto, Y. Tanaka, et al .......................... 414

**Short-Term Course of Chronic Hepatitis B and C Under Treatment with Etanercept Associated with Different DMARD without Antiviral Prophylaxis**
D.U. Cansu, T. Kalíoğlu, C. Korkmaz .......................... 421

**IgM-RF, Anti-CCP, and Anti-Citrullinated Human Fibrinogen Antibodies Decrease During Treatment with the TNF Blocker Infliximab in Patients with RA**

---

**Clinical and Immunologic Manifestations of MCTD in a Miami Population Compared to a Midwestern US Caucasian Population**
M.E. Maldonado, M. Perez, J. Pignac-Kobinger, et al .......................... 429

**DM and PM Associated with Malignancy: A 21-year Retrospective Study**
C. András, A. Pongy, T. Constantin, et al .......................... 438

**Epidemiology of Sporadic Inclusion Body Myositis and PM in Olmsted County, Minnesota**
P.C. Wilson, S.R. Ytterberg, J.L. St. Sauver, A.M. Reed .......................... 445

**Relapses in Patients with ANCA-Associated Vasculitis: Likely to Begin with the Same Organ as Initial Onset**
M. Chen, F. Yu, M-H. Zhao .......................... 448

**Anti-p53 Autoantibody in SSC: Association with Limited Cutaneous SSC**

**Assessment of Pulmonary Arterial Hypertension in Patients with SSC: Comparison of Noninvasive Tests with Results of Right-Heart Catheterization**
V.M. Hsu, A.E. Moreyra, A.C. Wilson, et al .......................... 458

---

**Does Incorporation of Aids and Devices Make a Difference in the Score of the HAQ-Disability Index?**
Analysis from a Scleroderma Clinical Trial
D. Khanna, P.J. Clements, A.E. Postlethwaite, D.E. Furst, for the Scleroderma Collagen Type 1 Study Group .......................... 466

**Reappraisal of the Effectiveness of MTX in PsA: Results from a Longitudinal Observational Cohort**
V. Chandran, C.T. Schentag, D.D. Gladman .......................... 469

**Treatment of PsA and RA with Disease Modifying Drugs — Comparison of Drugs and Adverse Reactions**
P.S. Hellwell, W.J. Taylor for the CASPAR Study Group .......................... 472

**Do We Really Need to Evaluate Entire Cervical Spines for Squaring Score in Modified Stoke AS Spinal Score?**

**A Comparison of Self-reported Joint Symptoms Following Infection with Different Enteric Pathogens: Effect of HLA-B27**
P. Schiellerup, K.A. Krogfelt, H. Locht .......................... 480

**Efficacy and Tolerability of IV Ibandronate Injections in Postmenopausal Osteoporosis: 2-Year Results from the DIVA Study**
J.A. Eisman, R. Civitelli, S. Adami, et al .......................... 488

---

**Contents continued opposite inside back cover**